AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
22 avr. 2020 08h05 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and PARIS, April 22, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company,...
AveXis receives positive CHMP opinion for Zolgensma®, the only gene therapy for spinal muscular atrophy (SMA)
27 mars 2020 08h59 HE
|
Novartis International AG
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, has been recommended for European Commission (EC) conditional approval for patients with spinal muscular atrophy (SMA) and...
Zolgensma® data shows rapid, significant, clinically meaningful benefit in SMA including prolonged event-free survival, motor milestone achievement and durability now up to 5 years post-dosing
24 mars 2020 02h15 HE
|
Novartis International AG
Interim SPR1NT data showed presymptomatic babies with SMA treated with Zolgensma® (onasemnogene abeparvovec-xioi) soon after birth achieved age-appropriate motor milestones In addition to meeting both...
AveXis presents AVXS-101 IT data demonstrating remarkable increases in HFMSE scores and a consistent clinically meaningful response in older patients with SMA Type 2
24 mars 2020 02h13 HE
|
Novartis International AG
SMA Type 2 patients between two and five years of age who received Dose B met the primary efficacy endpoint with a remarkable mean increase of 6.0 points in HFMSE scores from baseline to month 12,...
Novartis receives approval from Japanese Ministry of Health, Labour and Welfare for Zolgensma® the only gene therapy for patients with spinal muscular atrophy (SMA)
19 mars 2020 02h15 HE
|
Novartis International AG
Zolgensma® (onasemnogene abeparvovec), a one-time administered gene therapy, is approved for the treatment of SMA in patients under the age of two, including those who are pre-symptomatic at...
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
18 mars 2020 09h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. and CHAPEL HILL, N.C., March 18, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading clinical-stage adeno-associated virus (AAV) gene therapy...
APHL Announces Newborn Screening Systems Quality Improvement Projects Second Cohort Award Recipients
25 févr. 2020 11h15 HE
|
Association of Public Health Labs
Silver Spring, MD, Feb. 25, 2020 (GLOBE NEWSWIRE) -- The Association of Public Health Laboratories (APHL) is pleased to announce this year’s recipients of the Newborn Screening Systems Quality...
APHL Announces Newborn Screening Award Recipients
11 févr. 2020 12h01 HE
|
Association of Public Health Labs
Silver Spring, MD, Feb. 11, 2020 (GLOBE NEWSWIRE) -- The Association of Public Health Laboratories (APHL) is pleased to announce the fall 2019 recipients of the Expansion of Spinal Muscular Atrophy...
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
29 janv. 2020 10h27 HE
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a clinical-stage adeno-associated virus (AAV) gene therapy company, today introduced...
Visiongain launches new report on Gene Therapy R&D and Revenue Forecasts 2018-2028
05 sept. 2018 12h33 HE
|
Visiongain Ltd
LONDON, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Gene Therapy Market set to Grow at a CAGR of 41.1% in the first half of the forecast period. Visiongain has launched a new pharma report: Gene Therapy...